These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18630481)

  • 1. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer.
    Csejtei A; Tibold A; Varga Z; Koltai K; Ember A; Orsos Z; Feher G; Horvath OP; Ember I; Kiss I
    Anticancer Res; 2008; 28(3B):1917-22. PubMed ID: 18630481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer.
    Holley SL; Rajagopal R; Hoban PR; Deakin M; Fawole AS; Elder JB; Elder J; Smith V; Strange RC; Fryer AA
    Int J Oncol; 2006 Jan; 28(1):231-6. PubMed ID: 16328000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of polymorphism at p53, CYP1A1 and GSTM1 loci on p53 mutation and association of p53 mutation with prognosis in lung cancer.
    Wang YC; Chen CY; Wang HJ; Chen SK; Chang YY; Lin P
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):402-10. PubMed ID: 10418172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression.
    Mammano E; Belluco C; Bonafé M; Olivieri F; Mugianesi E; Barbi C; Mishto M; Cosci M; Franceschi C; Lise M; Nitti D
    Eur J Surg Oncol; 2009 Apr; 35(4):415-9. PubMed ID: 18468835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.
    Høgdall EV; Høgdall CK; Christensen L; Glud E; Blaakaer J; Bock JE; Vuust J; Nørgaard-Pedersen B; Kjaer SK
    Anticancer Res; 2002; 22(3):1859-64. PubMed ID: 12168882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients.
    Mojtahedi Z; Haghshenas MR; Hosseini SV; Fattahi MJ; Ghaderi A
    Indian J Cancer; 2010; 47(1):31-4. PubMed ID: 20071787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fish detected p53 deletion and N-MYC amplification in colorectal cancer.
    Ozakyol A; Ozdemir M; Artan S
    Hepatogastroenterology; 2006; 53(68):192-5. PubMed ID: 16608022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
    Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
    Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression.
    Zhu ZZ; Liu B; Wang AZ; Jia HR; Jin XX; He XL; Hou LF; Zhu GS
    J Zhejiang Univ Sci B; 2008 Nov; 9(11):847-52. PubMed ID: 18988302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping of p53 codon 175 in colorectal cancer.
    Krajewska WM; Stawińska M; Bryś M; Młynarski W; Witas HW; Okruszek A; Kiliańska ZM
    Med Sci Monit; 2003 May; 9(5):BR188-91. PubMed ID: 12761448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
    Rajkumar T; Samson M; Rama R; Sridevi V; Mahji U; Swaminathan R; Nancy NK
    Breast Cancer Res Treat; 2008 Nov; 112(1):81-7. PubMed ID: 18058229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
    Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
    Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients.
    Bau DT; Tsai MH; Lo YL; Hsu CM; Tsai Y; Lee CC; Tsai FJ
    Anticancer Res; 2007; 27(3B):1559-64. PubMed ID: 17595776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygosity for interleukin-18 -607 A/C polymorphism is associated with risk for colorectal cancer.
    Nikiteas N; Yannopoulos A; Chatzitheofylaktou A; Tsigris C
    Anticancer Res; 2007; 27(6B):3849-53. PubMed ID: 18225542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The associations of p53 overexpression with p53 codon 72 genetic polymorphism in esophageal cancer.
    Lee JM; Shun CT; Wu MT; Chen YY; Yang SY; Hung HI; Chen JS; Hsu HH; Huang PM; Kuo SW; Lee YC
    Mutat Res; 2006 Feb; 594(1-2):181-8. PubMed ID: 16318864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
    Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer.
    Hebbar M; Adenis A; Révillion F; Duhamel A; Romano O; Truant S; Libersa C; Giraud C; Triboulet JP; Pruvot FR; Peyrat JP
    Eur J Cancer; 2009 Jul; 45(10):1871-6. PubMed ID: 19361981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GSTM1 and codon 72 P53 polymorphism in multiple myeloma.
    Ortega MM; Honma HN; Zambon L; Lorand-Metze I; Costa FF; De Souza CA; Lima CS
    Ann Hematol; 2007 Nov; 86(11):815-9. PubMed ID: 17653713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.